The Critical Role of 'Hyper-Targeting' in Rare Disease Drug Development with Dan Donovan
insider.thefdagroup.com
The FDA Group’s Nick Capman sits down with Dan Donovan, an expert in rare disease drug development, to explore the unique challenges and new opportunities presented in the rare disease space.
The Critical Role of 'Hyper-Targeting' in Rare Disease Drug Development with Dan Donovan
The Critical Role of 'Hyper-Targeting' in…
The Critical Role of 'Hyper-Targeting' in Rare Disease Drug Development with Dan Donovan
The FDA Group’s Nick Capman sits down with Dan Donovan, an expert in rare disease drug development, to explore the unique challenges and new opportunities presented in the rare disease space.